Kalif Eliyahu Sharon 4

4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Mar 5, 2026

Form 4

Period: 2026-03-03

EVP, Chief Financial Officer

Transactions

Exercise/Conversion
Ordinary Shares
[F1][F2]
2026-03-03+49,800→ 107,278 total
Exercise/Conversion
Ordinary Shares
[F1][F2]
2026-03-03+141,478→ 248,756 total
Exercise/Conversion
Restricted Share Units
[F2][F3][F1]
2026-03-03−49,800→ 49,802 total
→ Ordinary Shares (49,800 underlying)
Exercise/Conversion
Restricted Share Units
[F2][F4][F1]
2026-03-03−141,478→ 0 total
→ Ordinary Shares (141,478 underlying)

Footnotes (4)

[F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
[F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
[F3]Restricted share units were granted on March 3, 2023, with 49,800 vested on each of March 3, 2024, March 3, 2025 and March 4, 2026, and 49,802 vesting on March 3, 2027.
[F4]Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on March 3, 2026, following satisfaction of the time-based vesting criteria.

Signature

/s/ Dov Bergwerk as attorney-in-fact for Eliyahu Sharon Kalif|2026-03-05

Documents

1 file